Ellinor currently helps to lead the AFGen Consortium, an international group of investigators studying the genetics of atrial fibrillation. Over the past 15 years, he has been continuously funded by the National Institutes of Health, he has received an Established Investigator Award from the American Heart Association (AHA), and he is a principal investigator on a Transatlantic Network of Excellence Program sponsored by the Fondation Leducq. Ellinor also co-leads a unique academic industrial partnership between the Broad and Bayer focused on identifying novel therapeutic targets for cardiovascular disease. He is a member of the AHA, the Heart Rhythm Society, and the American Society of Clinical Investigation.
I have always been intrigued with human genetics, so my research lab began with an initial focus on trying to identify the genetic basis of early-onset atrial fibrillation. This work in turn led the establishment of the AFGen Consortium, an international group of investigators studying the genetics of atrial fibrillation. In the ensuing years, we have led large-scale genetic analyses for atrial fibrillation and many other cardiovascular diseases. Our work now spans a wide range of topics centered on cardiovascular disease genetics, mechanisms, single cell sequencing, and therapeutic development.